Table IV.

Meta-analysis of observational studies with recent exposure to antenatal indomethacin (AI)

Neonatal Outcome	Reference	# Infants exposed to AI	# Infants unexposed to AI	Random-effects Odds ratio (95% C.I)	Heterogeneity Test p-value
IVH	23,31,32, 35,37,41	337	424	1.18 (0.57 – 2.4)	0.003
Grade III–IV IVH	23,31,32, 35,37	299	396	1.3 ( 0.5 – 3.2)	0.04
PVL	35,37	144	151	N/A	N/A
NEC	23,27,31, 32,35	268	1016	2.23 (1.16 – 4.25)	0.23
BPD	23,41	86	89	N/A	N/A
PDA	23,31,32, 35,37,41	337	434	1.05 (0.61 – 1.8)	0.01
RDS	23,35,37,41	239	246	2.2 (0.94 – 5.12)	0.02
Mortality	23,31,32, 35,37,41	339	436	1.15 (0.7 – 1.88)	0.2

N/A denotes not applicable